InsiderTrades

Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2026-07-17 21:00:20 ET · period of report 2026-07-16 · accession 0001140361-26-028844 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-07-17 21:00 2026-07-16 ADMA Kohler Terry CFO, Treas A - Grant $0.00 +85.1K 143.1K +147% $0
D 2026-07-17 21:00 2026-07-16 ADMA Kohler Terry CFO, Treas A - Grant $0.00 +136.4K 136.4K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-07-16 A A 85,130 $0.00 143,149 D — — (F1) These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. (F2) Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2 Derivative Stock Option (Right to Buy) 2026-07-16 A A 136,363 $0.00 136,363 D $8.81 · — to 2036-07-16 136,363 Common Stock (F3) This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.